Additional resources from our July 14 discussion on psychedelic medicine
The need for treatment of mental illness and substance use disorders continues to grow. The unrelenting burden, high costs of care, unmet demand, and gaps in efficacy all create a considerable opportunity for innovation. A new class of pharmaceuticals - psychedelic medicines - is among the emerging therapies and business models attracting attention.
On July 14, NEHI facilitated a discussion among experts who have been working in this area.
Below, please find additional resources shared by the panelists: